![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Synta Pharmaceuticals, Corp. |
---|---|
Information provided by: | Synta Pharmaceuticals, Corp. |
ClinicalTrials.gov Identifier: | NCT00088114 |
The purpose of this study is to determine the safety, toxicity and maximum tolerated dose of single doses of STA-4783/paclitaxel in combination when administered intravenously to patients with refractory cancer. To determine the pharmacokinetics of STA-4783 and paclitaxel when co-administered.
To assess the anti-tumor activity of STA-4783 and paclitaxel when co-administered.
Condition | Intervention | Phase |
---|---|---|
Neoplasms |
Drug: STA-4783/paclitaxel |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety Study |
Official Title: | A Phase I Trial of STA-4783 in Patients Receiving Paclitaxel for Treatment of Solid Tumors |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |
Beth Israel-Deaconess Medical Center | |
Boston, Massachusetts, United States, 02215 | |
Dana Farber Cancer Institute | |
Boston, Massachusetts, United States, 02215 |
Study ID Numbers: | 4783-01 |
Study First Received: | July 20, 2004 |
Last Updated: | October 5, 2007 |
ClinicalTrials.gov Identifier: | NCT00088114 |
Health Authority: | United States: Food and Drug Administration |
Paclitaxel |
Neoplasms Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses Mitosis Modulators |
Tubulin Modulators Antimitotic Agents Antineoplastic Agents, Phytogenic Pharmacologic Actions |